The EPS miss is mechanically driven by share dilution from the April offering (shares outstanding up 42% from Dec 2025) and higher R&D spend, not operational deterioration. The clinical data for muzastotug in MSS CRC and HCC is the primary catalyst — watch for randomized Phase 2 results in H1 2027 and potential registration trial start in 2027. The $127.9M cash runway into late 2028 removes near-term financing risk. The Sanofi collaboration adds external validation. Traders should monitor for any interim data updates or partnership expansions.
Price Chart
Executive Summary
Adagene reported H1 2026 net loss of $16.4M, wider than $13.5M in H1 2025, with EPS of -$0.23 vs consensus -$0.08 (a 187.5% miss). The company highlighted positive clinical data for muzastotug in MSS CRC and HCC, extended cash runway into late 2028 via a $70M April offering, and initiated a Sanofi collaboration. The EPS miss is significant for a pre-revenue biotech, but the clinical catalysts and cash position provide a counterbalance.
Key Financial Metrics
Key Facts
- H1 2026 net loss $16.4M vs $13.5M in H1 2025; EPS -$0.23 vs consensus -$0.08 (187.5% miss)
- Cash and equivalents $127.9M as of June 30, 2026, up from $74.5M at Dec 31, 2025, providing runway into late 2028
- Muzastotug 20 mg/kg Q3W in MSS CRC showed 36% ORR and median PFS 15.4 months; randomized Phase 2 results expected H1 2027
- Triple combination in 1L HCC showed 66.7% ORR vs 32.5% for active control at AACR
- Completed $70M public offering in April 2026; initiated global Phase 1/2 basket trial with Sanofi
- Net revenue $1.6M from Sanofi/Exelixis collaborations vs nil in H1 2025
Financial Impact
EPS miss of 187.5% vs consensus; net loss widened 21.5% YoY; cash burn rate ~$8.2M/quarter
Risk Factors
- Clinical trial failure in MSS CRC or HCC could significantly impair pipeline value
- Dilution from April offering (42% share increase) pressures EPS; further offerings possible
- China-based operations expose to geopolitical and regulatory risks
- Competition from other CTLA-4 and PD-1 combination therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3343553 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 6-K | $3.20 | awaiting T+60 | — | $2.49 (−22.19%) |
Sep 22, 2026 5w ago | 6-K | $3.23 | awaiting T+60 | — | $2.49 (−22.91%) |
Sep 10, 2026 6w ago | 6-K | $3.31 | awaiting T+60 | — | $2.49 (−24.77%) |
Sep 9, 2026 6w ago | 6-K | $3.27 | awaiting T+60 | — | $2.49 (−23.85%) |
Aug 16, 2026 10w ago | Institutional Cluster | $3.83 | awaiting T+60 | — | $2.49 (−34.99%) |
Aug 12, 2026 10w ago | 6-K | $3.75 | awaiting T+60 | — | $2.49 (−33.60%) |
Aug 12, 2026 10w ago | Press Release | $3.75 | awaiting T+60 | — | $2.49 (−33.60%) |
Jul 6, 2026 16w ago | 6-K | $3.93 $3.21 | ▼ −18.32% | ▼ −20.04% | $2.49 (−36.64%) |
Apr 17, 2026 27w ago | 6-K | $3.89 $3.67 | ▼ −5.66% | ▼ −12.43% | $2.49 (−35.99%) |
Apr 2, 2026 29w ago | 6-K | $3.99 $4.20 | ▼ −5.26% | ▲ +8.90% | $2.49 (+37.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers